Market Access Manager, EU Center

• Report to the Senior Director, Market Access, EU Center
• Collaborate with Medical Affairs, HEOR, Regulatory, Commercial and the global Market Access team
• Secure and sustain patient access to BridgeBio’s medicines across the DACH region
• Own the German AMNOG process end to end, from the value dossier under § 35a SGB V through reimbursement price negotiation with GKV-Spitzenverband under § 130b SGB V
• Lead regional market access through engagement with sickness funds, the Medical Service, regional physicians’ associations, hospitals and treating centres
• Plan, resource, quality-assure and submit AMNOG value dossiers to the G-BA
• Prepare scientific advice requests, written commenting procedures and oral hearings; manage procedural communications and timelines
• Develop pricing strategy, negotiation mandates, scenarios and European reference price analyses
• Engage federal and regional payers on reimbursement, cost-efficiency reviews and prior-authorisation practice
• Advise treating centres on NUB applications, DRG and additional-payment mapping, budget and price negotiations, drug committees and formulary listing
• Handle individual reimbursement requests, denials and claw-backs
• Lead reimbursement submissions in Austria and Switzerland
• Incorporate market access requirements into study design, evidence planning and launch planning

• Degree in health economics, pharmacy, medicine, life sciences or a comparable field
• 5–8 years of experience in market access or HTA
• Demonstrated experience preparing AMNOG value dossiers under § 35a SGB V, ideally as project lead on at least one complete procedure
• Hands-on involvement in a reimbursement price negotiation under § 130b SGB V
• Solid command of G-BA and IQWiG methodology, procedural rules and statutory timelines
• Ability to appraise clinical evidence critically and translate it into payer-ready argumentation
• Experience engaging payers and/or hospitals directly on reimbursement matters
• Knowledge of German hospital financing (NUB, DRG, additional payments)
• Knowledge of reimbursement in Austria and Switzerland is a strong plus
• Strong written argumentation and ability to work autonomously
• Experience with orphan drugs or a limited evidence base is an advantage
• Business-fluent German and English
• Willingness to travel approximately 20% of working time

• Market-leading compensation
• Hybrid work model with flexibility
• Career development through regular feedback, continuous education and professional development programs
• Financial rewards, peer-to-peer recognition, and growth opportunities
• Flexible, “take-what-you-need” paid time off and company-paid holidays
• Comprehensive paid medical and parental leave
• Professional development programs via LinkedIn Learning, LifeLabs, and BetterUp Coaching
• Internal mobility and skill development opportunities
• Approximately 20% travel is anticipated